Spain Alzheimer’s Disease Drugs Market Report 2022 to 2030

Spain Alzheimer’s Disease Drugs Market Analysis

$ 3999

Spain's Alzheimer’s disease drugs market was valued at $298 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.42% from 2022 to 2030 and will reach $528 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are AstraZeneca, Biogen, Daiichi Sankyo Company, Eisai Co., Eli Lilly and Company, Johnson and Johnson, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co., Novartis AG, STA Pharmaceutical, Pfizer and Catalent among others.

ID: IN10ESPH006 CATEGORY: Pharmaceuticals GEOGRAPHY: Spain AUTHOR: Nandini Shah

Buy Now

Spain Alzheimer’s Disease Drugs Market Executive Summary

Spain's Alzheimer’s disease drugs market was valued at $298 Mn in 2022 and is estimated to expand at a CAGR of 7.42% from 2022-30 and will reach $528 Mn in 2030. Alzheimer's disease is characterized by nerve cell degeneration throughout the brain. It impairs cognitive function, including memory, language, thinking, and behavior. Alzheimer’s disease (AD) is the most common type of dementia. Little is known about the origin of Alzheimer's disease and the risk factors that contribute to it. Current evidence suggests that a well-balanced diet and moderate alcohol intake can postpone cognitive decline and lower AD risk whereas obesity, overweight, and environmental exposure can raise AD risk.

More than 800,000 people in Spain have Alzheimer's disease. At least 44 Mn individuals worldwide suffer from dementia, making the disease a global health catastrophe that must be addressed. Spain stated in October 2019 that it had adopted a National Strategy for Alzheimer's and other dementias. The strategy follows the conclusion of the Neurodegenerative Diseases Strategy, which ran from 2016 to 2019 and includes particular Alzheimer's disease measures.

spain alzheimers disease drugs market analysis

Market Dynamics

Market Growth Drivers

In Spain, over 700,000 people over the age of 40 are already living with Alzheimer's and other dementias, a figure that is expected to more than double to 2 Mn by 2050. As the population ages, the number of people suffering from Alzheimer's disease in Spain is expected to increase. This is driving the demand for drugs that can help manage the symptoms of the disease. The Spanish government has taken several initiatives to support the development of new drugs for Alzheimer's disease. For instance, the government has invested in research to better understand the disease and to develop new treatments. As awareness about Alzheimer's disease increases among the general public, more people are seeking diagnosis and treatment. This is driving demand for drugs that can help manage the symptoms of the disease.

Technological advancements in the field of drug development are enabling the development of new drugs that can better treat Alzheimer's disease. For example, advances in genetics and biomarkers are helping researchers to better understand the disease and develop more effective treatments. The regulatory environment in Spain is favorable for the development and approval of new drugs for Alzheimer's disease. This is encouraging pharmaceutical companies to invest in the development of new treatments.

Market Restraints

Alzheimer's drugs can be expensive, and this can limit access for some patients. This is particularly challenging in Spain, where the public healthcare system is the main provider of healthcare services. While there are drugs available to treat Alzheimer's disease, their effectiveness is limited. There is a need for new and more effective drugs that can better manage the symptoms of the disease. There are currently no disease-modifying treatments available for Alzheimer's disease, meaning that drugs can only manage the symptoms of the disease, rather than treat its underlying causes. There is a need for better disease management strategies that can improve outcomes for patients with Alzheimer's disease. This includes better access to social and community-based services, as well as more comprehensive care plans. While the Spanish government has invested in research for Alzheimer's disease, funding remains limited compared to other disease areas. This can limit the development of new treatments and slow progress toward better disease management strategies.

Competitive Landscape

Key Players

AstraZeneca
Biogen
Daiichi Sankyo Company
Eisai Co.
Eli Lilly and Company
H. Lundbeck A/S
Johnson and Johnson
F. Hoffmann-La Roche AG
Merck & Co.
Pfizer
Catalent
STA Pharmaceutical

Healthcare Policies and Regulatory Landscape

Spain's National Plan on Alzheimer's Disease and Other Neurodegenerative Disorders is a public health policy initiative aimed at improving the prevention, diagnosis, treatment, and care of patients with Alzheimer's disease and other neurodegenerative disorders. The plan was launched in 2019 and is a joint effort of the Spanish Ministry of Health, Social Services and Equality, the Spanish Ministry of Science, Innovation, and Universities, and other public and private institutions.

The healthcare policy on Alzheimer's drugs market in Spain is focused on ensuring access to effective treatments for patients while also managing costs. The Spanish healthcare system is based on a publicly-funded National Health System (Sistema Nacional de Salud), which provides universal coverage to all residents of Spain. The government has taken several initiatives to support the development and access to Alzheimer's drugs in Spain. For instance, the government has invested in research to better understand the disease and to develop new treatments. In addition, the government has implemented policies to ensure that patients have access to effective treatments at affordable prices.

One key policy in this regard is the establishment of the Inter-Ministerial Commission for Pricing of Medicines (Comisión Interministerial de Precios de los Medicamentos), which sets prices for all medicines in Spain, including Alzheimer's drugs. This policy is aimed at ensuring that prices for drugs are affordable for patients while also supporting the development of new treatments.

Reimbursement Scenario

In Spain, the reimbursement scenario for Alzheimer's drugs is primarily governed by the public healthcare system. The Spanish healthcare system is based on a publicly-funded National Health System (Sistema Nacional de Salud), which provides universal coverage to all residents of Spain. Under the public healthcare system, Alzheimer's drugs are included in the list of medications that are covered by the system. This means that patients have access to these drugs, regardless of their ability to pay.

The reimbursement scenario for Alzheimer's drugs in Spain is governed by the Inter-Ministerial Commission for Pricing of Medicines (Comisión Interministerial de Precios de los Medicamentos), which sets prices for all medicines in Spain, including Alzheimer's drugs. The commission determines the maximum price that can be charged for each drug, considering its therapeutic value and the cost of producing it.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Alzheimer's Disease Drugs Market Segmentation

By Drug Class (Revenue, USD Billion)

Cholinesterase Inhibitors (Donepezil, Rivastigmine, Galantamine)
N-Methyl-D-Aspartate (NMDA) Receptor Antagonists (Memantine)
Combination Drugs
Others (Lecanemab, Aducanumab)

Drug segmentation is the process of dividing a set of drugs into different categories or classes based on their pharmacological properties, therapeutic uses, and other characteristics. Here, Alzheimer’s Disease Drugs Market is segmented into Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Combination Drugs, and others like (Lecanemab, Aducanumab).

By Distribution Channel (Revenue, USD Billion)

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Route of Administration

Oral
Transdermal
Intravenous

Insights10 will provide you with the reports within 10 key parameters which are:

Market Overview
Market Growth Drivers & Restraints
Epidemiology of Disease Type
Market Segmentation
Market Share
Competitive Landscape
Key Company Profiles
Healthcare Policies & Regulatory Framework
Reimbursement Scenario
Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

Establishing market drivers and trends
Analyzing the regulatory landscape to understand future growth
Market Segment based analysis to obtain revenue/volume
Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to oﬀer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.